
Jade Biosciences, Inc. — Investor Relations & Filings
Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 | 2026-05-15 | English | |
| S-8 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| 424B3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| 8-K - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-04-22 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46362227 | 424B3 | 2026-05-15 | English | ||
| 43597502 | S-8 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43589318 | S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43582556 | S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43524504 | 424B3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 35226913 | 8-K - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-04-22 | English | ||
| 31760251 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31760104 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31760021 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31760250 | 4 Filing | 2026-02-13 | English | ||
| 31760064 | 4 Filing | 2026-02-13 | English | ||
| 31760005 | 4 Filing | 2026-02-13 | English | ||
| 31759976 | 4 Filing | 2026-02-13 | English | ||
| 31759919 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 31760179 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
D.Western Therapeutics Institute, Inc.
Biotechnology firm developing drugs from a proprietary prot…
|
4576 | JP | Professional, scientific and te… |
|
Ecopia BioSciences Inc.
Developing novel anticancer agents and therapeutic solution…
|
EIA | CA | Professional, scientific and te… |
|
Ectin Research AB
Pharmaceutical company developing novel oncology treatments…
|
ECTIN B | SE | Professional, scientific and te… |
|
EdgeLab S.p.A.
Designs and manufactures marine and underwater solutions, i…
|
ELB | IT | Professional, scientific and te… |
|
Editas Medicine, Inc.
A clinical-stage genome editing company developing CRISPR m…
|
EDIT | US | Professional, scientific and te… |
|
EGF Theramed Health Corp.
Developing psychedelic drugs for mental health, diagnostic …
|
TMED | CA | Professional, scientific and te… |
|
Eikon Therapeutics, Inc.
Integrates live-cell imaging and computing to discover ther…
|
EIKN | US | Professional, scientific and te… |
|
Eledon Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for organ and a…
|
ELDN | US | Professional, scientific and te… |
|
Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and …
|
ELIC | SE | Professional, scientific and te… |
|
Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immun…
|
ELTX | US | Professional, scientific and te… |
Jade Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33383/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33383 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33383 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33383 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33383}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Jade Biosciences, Inc. (id: 33383)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.